CAG
VRTX icon

Csenge Advisory Group’s Vertex Pharmaceuticals VRTX Stock Holding History

Csenge Advisory Group’s Portfolio VRTX Stock Details VRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$254K Sell
511
-90
-15% -$39.9K 0.01% 660
2026
Q1 		$269K Sell
601
-975
-62% -$455K 0.01% 605
2025
Q4 		$714K Sell
1,576
-216
-12% -$93.1K 0.03% 363
2025
Q3 		$702K Sell
1,792
-304
-15% -$127K 0.03% 370
2025
Q2 		$927K Sell
2,096
-85
-4% -$39.2K 0.05% 278
2025
Q1 		$1.07M Buy
2,181
+37
+2% +$17.2K 0.06% 243
2024
Q4 		$863K Sell
2,144
-828
-28% -$384K 0.05% 294
2024
Q3 		$1.43M Sell
2,972
-430
-13% -$207K 0.07% 201
2024
Q2 		$1.59M Buy
3,402
+638
+23% +$277K 0.09% 170
2024
Q1 		$1.16M Buy
2,764
+258
+10% +$109K 0.06% 233
2023
Q4 		$1.02M Buy
2,506
+439
+21% +$162K 0.06% 234
2023
Q3 		$719K Buy
2,067
+114
+6% +$39.9K 0.05% 281
2023
Q2 		$687K Buy
1,953
+223
+13% +$75.1K 0.05% 299
2023
Q1 		$545K Buy
1,730
+342
+25% +$103K 0.04% 320
2022
Q4 		$401K Buy
1,388
+178
+15% +$54.2K 0.03% 398
2022
Q3 		$350K Buy
+1,210
New +$348K 0.03% 423
2018
Q4 		– Sell
-51
Closed -$8K – 1460
2018
Q3 		$8K Buy
+51
New +$9.08K ﹤0.01% 551

Other funds holding VRTX

Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

Csenge Advisory Group's VRTX Position: Q2 2026 in Review

Csenge Advisory Group reduced its Vertex Pharmaceuticals (VRTX) stake by 15% in Q2 2026, selling an estimated $39.9K and leaving 511 shares worth $254K. The position accounts for 0.01% of the portfolio, ranked #660.

Csenge Advisory Group first reported a position in VRTX in Q3 2018 and has held it in 17 quarters since. The position peaked at $1.59M in Q2 2024. 1,747 funds tracked by Wall St. Rank hold VRTX as of Q2 2026.

  • Csenge Advisory Group held 511 shares of Vertex Pharmaceuticals worth $254K as of Q2 2026.
  • Csenge Advisory Group sold 90 Vertex Pharmaceuticals shares in Q2 2026, an estimated $39.9K.
  • Vertex Pharmaceuticals made up 0.01% of Csenge Advisory Group's portfolio in Q2 2026, its #660 holding.
  • Csenge Advisory Group first reported a position in Vertex Pharmaceuticals in Q3 2018 and has held it in 17 quarters since.
  • Csenge Advisory Group's Vertex Pharmaceuticals position peaked at $1.59M in Q2 2024.
  • 1,747 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q2 2026.

Based on Csenge Advisory Group's 13F filing for Q2 2026, filed 10 Aug 2026.